help button home button Endocrine Society JCEM JCEM Call for Nominations for EIC
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Submit a related Letter to the Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Noth, R. H.
Right arrow Articles by Havelick, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Noth, R. H.
Right arrow Articles by Havelick, J.

Journal of Clinical Endocrinology & Metabolism, Vol 51, 64-69, Copyright © 1980 by Endocrine Society

ARTICLES

Tonic dopaminergic suppression of plasma aldosterone

RH Noth, RW McCallum, C Contino and J Havelick

To investigate the interaction between dopamine and aldosterone in man, either the dopamine antagonist, metoclopramide [methoxy-2-chloro-5- procainamide (M)], or a placebo was given by an iv bolus in a random, double blind fashion to nine supine volunteers on a hospital diet (mean urinary sodium excretion, 135 +/- 17 vs. 145 +/- 26 meq/24 h; P = NS). After M (10 mg), plasma aldosterone (PA) rose from 6.4 +/- 1.1 to 14.0 +/- 2.2 (SEM) ng/dl (P less than 0.01) within 15 min. PRA, potassium, and cortisol were unchanged. PRL increased 10-fold, but individual increments in PA and PRL did not correlate significantly. Oral M (10 mg) produced a rise in PA in only two of five volunteers. To determine whether the increase in PA was due to the dopamine antagonist properties of M, the iv study was repeated in four of the volunteers during an ongoing dopamine infusion. The integrated incremental change in PA during the hour after M administration was markedly blunted (399 +/- 56 vs. 69 +/- 32 ng/dl.min; P less than 0.05), and the PRL response was totally abolished. Assuming no major effects of M on the MCR of aldosterone, these data suggest a tonic inhibitory influence of dopamine on aldosterone secretion.


This article has been cited by other articles:


Home page
 Eur J EndocrinolHome page
R. Pivonello, D. Ferone, G. Lombardi, A. Colao, S. W J Lamberts, and L. J Hofland
Novel insights in dopamine receptor physiology
Eur. J. Endocrinol., April 1, 2007; 156(suppl_1): S13 - S21.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
R. Pivonello, D. Ferone, W. W. de Herder, R. R. de Krijger, M. Waaijers, D. M. Mooij, P. M. van Koetsveld, A. Barreca, M. L. Del Basso De Caro, G. Lombardi, et al.
Dopamine Receptor Expression and Function in Human Normal Adrenal Gland and Adrenal Tumors
J. Clin. Endocrinol. Metab., September 1, 2004; 89(9): 4493 - 4502.
[Abstract] [Full Text] [PDF]

Home page
 Physiol. Rev.Home page
C. MISSALE, S. R. NASH, S. W. ROBINSON, M. JABER, and M. G. CARON
Dopamine Receptors: From Structure to Function
Physiol Rev, January 1, 1998; 78(1): 189 - 225.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1980 by The Endocrine Society